1238376-16-3

Basic information

• Product Name: N-[3-(2-amino-1H-benzimidazol-6-yl)-4-methylphenyl]-3-(trifluoromethyl)benzamide
• Synonyms: N-[3-(2-amino-1H-benzimidazol-6-yl)-4-methylphenyl]-3-(trifluoromethyl)benzamide
• CAS NO: 1238376-16-3
• Molecular Weight: 410.398
• Mol File: 1238376-16-3.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-[3-(2-amino-1H-benzimidazol-6-yl)-4-methylphenyl]-3-(trifluoromethyl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-[3-(2-amino-1H-benzimidazol-6-yl)-4-methylphenyl]-3-(trifluoromethyl)benzamide(1238376-16-3)
• EPA Substance Registry System: N-[3-(2-amino-1H-benzimidazol-6-yl)-4-methylphenyl]-3-(trifluoromethyl)benzamide(1238376-16-3)

Safety Data

• Hazardous Substances Data: 1238376-16-3(Hazardous Substances Data)

Upstream product

• 876322-58-6 N-[4-methyl-3-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-3-trifluoromethyl-benzamide 
• 5418-93-9 6-chloro-1H-benzoimidazol-2-amine 

Relevant articles and documents

EPHA4 RTK INHIBITORS FOR TREATMENT OF NEUROLOGICAL AND NEURODEGENERATIVE DISORDERS AND CANCER

The present invention is directed to compounds of generic formula (I) which are inhibitors of ephrin A4. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases regulated by the EphA4 RTK signaling, such as neurological and neurodegenerative disorders and cancer.